Company intelligence / Profile preview
Atamyo Therapeutics
Evry, Ile de France, Franceatamyo.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Atamyo has completed recruitment for the dose escalation phase of its Phase 1b study of ATA-100 for LGMD2I/R9. ATA-200 for LGMD2C/R5 has received regulatory authorization in Europe and FDA clearance for clinical trials, with patient dosing expected to begin before the end of 2024.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Gene therapyAAV-based gene therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Genethon
Beyond the preview
Go deeper on Atamyo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atamyo Therapeutics.